Biased ligand quantification in drug discovery: From theory to high throughput screening to identify new biased μ opioid receptor agonists

British Journal of Pharmacology

Volumn 173, Issue 8, 2016, Pages 1393-1403

  Winpenny, David ^a   Clark, Mellissa ^a   Cawkill, Darren ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; BETA ARRESTIN 2; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LOPERAMIDE; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR AGONIST; OLICERIDINE; OXYCODONE; LIGAND; MU OPIATE RECEPTOR;

AGONIST POTENCY; ARTICLE; BINDING AFFINITY; CAMP ASSAY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; EC50; ENZYME INHIBITION; GTPGAMMAS BINDING ASSAY; HIGH THROUGHPUT SCREENING; LIGAND BIAS THEORY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING ASSAY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THEORY; AGONISTS; ANIMAL; CELL CULTURE; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG DEVELOPMENT; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLISM;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIGANDS; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84959551995     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13441     Document Type: Article

References (42)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744-5869.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015c). The Concise guide to PHARMACOLOGY 2015/2016: Overview. Br J Pharmacol 172: 5729-5743.
4. Allen JA, Yost JM, Setola V, Chen X, Sassanoa MF, Chenc M, et al., (2011). Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 108: 18488-18493.
5. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al., (2003). β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100: 11406-11411.
6. Baker JG, Hall IP, Hill SJ, (2003). Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol 64: 1357-1369.
7. Black JW, Leff P, (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162.
8. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr, (2012). TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 5: 627-634.
9. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT, (1999). Enhanced morphine analgesia in mice lacking β-Arrestin 2. Science 286: 2495-2498.
10. Brust TF, Hayes DL, Roman DL, Burris KD, Watts VJ, (2015). Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signalling pathways. J Pharmacol Exp Ther 352: 480-493.
11. Charfi N, Audet H, Bagheri Tudashki H, Pineyro G, (2015). Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands. Br J Pharmacol 172: 435-448.
12. Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, et al., (2013). Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem 56: 8019-8031.
13. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
14. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, et al., (2013). G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717.
15. Ehlert FJ, Griffin MT, Sawyer GW, Bailon R, (1999). A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M3 muscarinic receptors in guinea pig ileum and transfected cells. J Pharmacol Exp Ther 289: 981-992.
16. 4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328: 331-342.
17. Gaborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, Hunyady L, (2003). The role of a conserved region of the second intracellular loop in at1 angiotensin receptor activation and signalling. Endocrinology 144: 2220-2228.
18. Galandrin S, Bouvier M, (2006). Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 1575-1584.
19. Griffin MT, Figueroa KW, Liller S, Ehlert FJ, (2007). Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15. J Pharmacol Exp Ther 321: 1193-1207.
20. Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, et al., (2014). Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol 171: 1180-1194.
21. Kenakin T, (2013). New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol 168: 554-575.
22. Kenakin T, Christopoulos A, (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
23. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
24. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S, (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3: 193-203.
25. Nickolls SA, Waterfield A, Williams RE, Kinloch RA, (2011). Understanding the effect of different assay formats on agonist parameters: a study using the mu-opioid receptor. J Biomol Screen 16: 706-716.
26. Nickolls SA, Humphreys S, Clark M, McMturray G, (2013). Co-expression of GRK2 reveals a novel conformational state of the μ-opioid receptor. PLoS One 8 e83691. doi: 10.1371/journal.pone.0083691.
27. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
28. Raehal KM, Walker JKL, Bohn LM, (2005). Morphine side effects in β-arrestin 2 knockout mice. J Pharmacol Exp Ther 314: 1195-1201.
29. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald WG, Lam CM, DeWire SM, et al., (2011). Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80: 367-377.
30. Rives ML, Rossillo M, Liu-Chen LY, Javitch JA, (2012). 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem 287: 27050-27054.
31. Rominger DH, Cowan CL, Gowen-MacDonald W, Violin JD, (2014). Biased ligands: pathway validation for novel GPCR therapeutics. Curr Opin Pharmacol 16: 108-115.
32. Shonberg J, Herenbrink CK, Lopez L, Christopoulos A, Scammells PJ, Capuano B, et al., (2013). A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 56: 9199-9221.
33. Shukla AK, Singh G, Ghosh E, (2014). Emerging structural insights into biased GPCR signalling. Trends Biochem Sci 39: 594-602.
34. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, et al., (2014). Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155: 1829-1835.
35. Stahl EL, Zhou L, Ehlert FJ, Bohn LM, (2015). A novel method for analysing extremely biased agonism at G-protein coupled receptors. Mol Pharmacol 87: 866-877.
36. Thompson GL, Kelly E, Christopoulos A, Canals M, (2015a). Novel GPCR paradigms at the μ-opioid receptor. Br J Pharmacol 172: 287-296.
37. Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M, (2015b). Biased agonism of endogenous opioid peptides at the mu-opioid recptor. Mol Pharmacol 88: 335-346.
38. van der Westhuizen ET, Breton B, Christopoulos A, Bouvier M, (2014). Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 85: 492-509.
39. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al., (2003). Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 100: 10782-10787.
40. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al., (2007). A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signalling. Proc Natl Acad Sci U S A 104: 6657-16662.
41. Zhang J, Ferguson SSG, Barak LS, Bodduluri SR, Laporte SA, Law PY, et al., (1998). Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness. Proc Natl Acad Sci U S A 95: 7157-7162.
42. Zhao P, Lieu T, Barlow N, Metcalf M, Veldhuis NA, Jensen DD, et al., (2014). Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J Biol Chem 280: 27215-27234.